<--- Back to Details
First PageDocument Content
Interstitial cystitis / Benign prostatic hyperplasia / Urinary incontinence / Urology / Prostate cancer / Vesicoureteral reflux / Dysuria / Chronic prostatitis/chronic pelvic pain syndrome / Bladder exstrophy / Medicine / Health / Lower urinary tract symptoms
Date: 2013-09-13 07:16:56
Interstitial cystitis
Benign prostatic hyperplasia
Urinary incontinence
Urology
Prostate cancer
Vesicoureteral reflux
Dysuria
Chronic prostatitis/chronic pelvic pain syndrome
Bladder exstrophy
Medicine
Health
Lower urinary tract symptoms

Add to Reading List

Source URL: media.wiley.com

Download Document from Source Website

File Size: 104,15 KB

Share Document on Facebook

Similar Documents

6-Day Intensive Treatment Protocol for Refractory Chronic Prostatitis/Chronic Pelvic Pain Syndrome Using Myofascial Release and Paradoxical Relaxation Training

DocID: 1d69x - View Document

Interstitial cystitis / Cystitis / Chronic prostatitis/chronic pelvic pain syndrome / Glomerulation / Urination / Urinary bladder disease / Bladder cancer / Urinary retention / Urinary bladder / Medicine / Health / Urology

http://www.reuters.com/articlePrint?articleId=US180628%2B24-Jun

DocID: 19NC0 - View Document

Interstitial cystitis / Chronic prostatitis/chronic pelvic pain syndrome / Cystitis / Overactive bladder / Urinary bladder disease / Urination / Urinary tract infection / Urinary urgency / Bladder cancer / Medicine / Health / Urology

TARIS® Secures $12.5 Million in Additional Financing; Initiates Phase 2 Trial of Lead Product Candidate Lexington, MA – April 2nd, 2013 – TARIS Biomedical®, a specialty pharmaceutical company developing innovative,

DocID: 19L9P - View Document

Interstitial cystitis / Bladder cancer / Cystitis / Urination / Overactive bladder / Chronic prostatitis/chronic pelvic pain syndrome / Urinary bladder disease / Urinary tract infection / Urinary bladder / Medicine / Health / Urology

TARIS SUCCESSFULLY COMPLETES PHASE 1 STUDY -- First Human Trial Enables Development for Several Indications -Lexington, MA – December 2, 2009 – TARIS Biomedical, a specialty pharmaceutical company pioneering the fiel

DocID: 19F0k - View Document

Interstitial cystitis / Chronic prostatitis/chronic pelvic pain syndrome / Cystitis / Bladder cancer / Urinary tract infection / Overactive bladder / Urinary urgency / Urinary bladder disease / Urination / Medicine / Health / Urology

TARIS® Announces Dosing of First Patient in Second Phase 2 Clinical Study of LiRIS® in Interstitial Cystitis Lexington, MA – April 2nd, 2013 – TARIS Biomedical®, a specialty pharmaceutical company developing innov

DocID: 19AVH - View Document